BioSpace News Archive

Gelesis announced the presentation of data from a clinical study demonstrating that GS500 prototype provided a significant reduction in colonic transit time in patients with chronic idiopathic constipation relative to placebo.

New Board Members Elected at The Aesthetic Meeting 2019 in New Orleans

ResMed revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society’s ATS 2019 International Conference.

New funding to support platform advancements and proprietary pipeline expansion

Mission to Include Breast Implant Illness Research and Funding for Data Collection and Standardization Technology

When people with Crohn’s disease worked together with their gastroenterologists to detect and address worsening symptoms sooner – using SonarMD’s care coordination solution – they were more likely to stay out of the hospital.

Takeda Pharmaceutical Company Limited announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab was superior to the anti-tumor necrosis factor-alpha biologic adalimumab in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis.